Skip to main content
Erschienen in: Current Pain and Headache Reports 11/2018

01.11.2018 | Migraine and Beyond (R Cowan, Section Editor)

Is Medication Overuse Drug Specific or Not? Data from a Review of Published Literature and from an Original Study on Italian MOH Patients

verfasst von: Licia Grazzi, Eleonora Grignani, Domenico D’Amico, Emanuela Sansone, Alberto Raggi

Erschienen in: Current Pain and Headache Reports | Ausgabe 11/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The aim is twofold. First, to give an insight on the role exerted by different classes of drugs in favouring migraine chronification. Second, to explore the relationship between type and amount of overused medications and history of previous withdrawal treatment and of frequent relapses.

Recent Findings

All drug classes were found to favour migraine chronification. No data are available for the association with relapses into CM-MOH. Our clinical study shows that patients who underwent previous withdrawal treatments were more likely to be overusers of multiple drug classes and overuse higher amounts of symptomatic medications, particularly, indomethacin, eletriptan and tramadol. Frequent relapsers were more likely to be overusers of opioids or ergotamine and caffeine derivates or of multiple classes, particularly acetylsalicylic acid and ergotamine/caffeine derivates.

Summary

The joint results our review and clinical study do not seem to support the idea that MOH is drug-specific: rather, it points out that all drug classes may induce migraine chronification. Those drugs which are at higher risk of overuse are among those preferred by the “worst” patients, i.e. those who needed one or more withdrawal treatments for MOH. Our results reinforce the clinical impression that patients with CM and MOH, and particularly the most difficult to treat for their poor response to withdrawal treatments, are characterised by a particular drive towards the consumption of “whatever is likely to be perceived to provide some relief”, despite these drugs that are perceived as “more powerful”, are often indicated as second- or third-line medications.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat International Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd ed. Cephalalgia. 2018;38:1–211. International Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd ed. Cephalalgia. 2018;38:1–211.
2.
Zurück zum Zitat •• Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache. 2008;48(8):1157–68. This is one of the first and most important studies addressing the risk of chronification connected to the use of acute medications. CrossRefPubMed •• Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache. 2008;48(8):1157–68. This is one of the first and most important studies addressing the risk of chronification connected to the use of acute medications. CrossRefPubMed
3.
Zurück zum Zitat Raggi A, Schiavolin S, Leonardi M, Giovannetti AM, Bussone G, Curone M, et al. Chronic migraine with medication overuse: association between disability and quality of life measures, and impact of disease on patients’ lives. J Neurol Sci. 2015;348(1–2):60–6.CrossRefPubMed Raggi A, Schiavolin S, Leonardi M, Giovannetti AM, Bussone G, Curone M, et al. Chronic migraine with medication overuse: association between disability and quality of life measures, and impact of disease on patients’ lives. J Neurol Sci. 2015;348(1–2):60–6.CrossRefPubMed
4.
Zurück zum Zitat Andrasik F, Grazzi L, Usai S, Kass S, Bussone G. Disability in chronic migraine with medication overuse: treatment effects through 5 years. Cephalalgia. 2010;30:610–4.CrossRefPubMed Andrasik F, Grazzi L, Usai S, Kass S, Bussone G. Disability in chronic migraine with medication overuse: treatment effects through 5 years. Cephalalgia. 2010;30:610–4.CrossRefPubMed
5.
Zurück zum Zitat Raggi A, Leonardi M, Giovannetti AM, Schiavolin S, Bussone G, Grazzi L, et al. A 14-month study of change in disability and mood state in patients with chronic migraine associated to medication overuse. Neurol Sci. 2013;34(Suppl 1):139–40.CrossRef Raggi A, Leonardi M, Giovannetti AM, Schiavolin S, Bussone G, Grazzi L, et al. A 14-month study of change in disability and mood state in patients with chronic migraine associated to medication overuse. Neurol Sci. 2013;34(Suppl 1):139–40.CrossRef
6.
Zurück zum Zitat Bendtsen L, Munksgaard S, Tassorelli C, Nappi G, Katsarava Z, Lainez M, et al. Disability, anxiety and depression associated with medication-overuse headache can be considerably reduced by detoxification and prophylactic treatment. Results from a multicentre, multinational study (COMOESTAS project). Cephalalgia. 2014;34:426–33.CrossRefPubMed Bendtsen L, Munksgaard S, Tassorelli C, Nappi G, Katsarava Z, Lainez M, et al. Disability, anxiety and depression associated with medication-overuse headache can be considerably reduced by detoxification and prophylactic treatment. Results from a multicentre, multinational study (COMOESTAS project). Cephalalgia. 2014;34:426–33.CrossRefPubMed
7.
Zurück zum Zitat Lantéri-Minet M, Duru G, Mudge M, Cottrell S. Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review. Cephalalgia. 2011;31:837–50.CrossRefPubMed Lantéri-Minet M, Duru G, Mudge M, Cottrell S. Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review. Cephalalgia. 2011;31:837–50.CrossRefPubMed
8.
Zurück zum Zitat Raggi A, Giovannetti AM, Leonardi M, Schiavolin S, D’Amico D, Curone M, et al. Disability and mood state in patients with episodic and chronic migraine associated to medication overuse. Neurol Sci. 2012;33(Suppl 1):169–71.CrossRef Raggi A, Giovannetti AM, Leonardi M, Schiavolin S, D’Amico D, Curone M, et al. Disability and mood state in patients with episodic and chronic migraine associated to medication overuse. Neurol Sci. 2012;33(Suppl 1):169–71.CrossRef
9.
Zurück zum Zitat Bigal ME, Lipton RB. Concepts and mechanisms of migraine chronification. Headache. 2008;48(1):7–15.CrossRefPubMed Bigal ME, Lipton RB. Concepts and mechanisms of migraine chronification. Headache. 2008;48(1):7–15.CrossRefPubMed
10.
11.
Zurück zum Zitat Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30(5):599–609.CrossRefPubMed Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30(5):599–609.CrossRefPubMed
12.
Zurück zum Zitat D’Andrea G, D’Amico D, Bussone G, Bolner A, Aguggia M, Saracco MG, et al. The role of tyrosine metabolism in the pathogenesis of chronic migraine. Cephalalgia. 2013;33:932–7.CrossRefPubMed D’Andrea G, D’Amico D, Bussone G, Bolner A, Aguggia M, Saracco MG, et al. The role of tyrosine metabolism in the pathogenesis of chronic migraine. Cephalalgia. 2013;33:932–7.CrossRefPubMed
13.
Zurück zum Zitat Misra UK, Kalita J, Tripathi GM, Bhoi SK. Is β-endorphin related to migraine headache and its relief? Cephalalgia. 2013;33:316–22.CrossRefPubMed Misra UK, Kalita J, Tripathi GM, Bhoi SK. Is β-endorphin related to migraine headache and its relief? Cephalalgia. 2013;33:316–22.CrossRefPubMed
14.
Zurück zum Zitat Cevoli S, Sancisi E, Grimaldi D, Pierangeli G, Zanigni S, Nicodemo M, et al. Family history for chronic headache and drug overuse as a risk factor for headache chronification. Headache. 2009;49:412–8.CrossRefPubMed Cevoli S, Sancisi E, Grimaldi D, Pierangeli G, Zanigni S, Nicodemo M, et al. Family history for chronic headache and drug overuse as a risk factor for headache chronification. Headache. 2009;49:412–8.CrossRefPubMed
15.
Zurück zum Zitat Evers S, Jensen R. Treatment of medication overuse headache guideline of the EFNS headache panel. Eur J Neurol. 2011;18:1115–21.CrossRefPubMed Evers S, Jensen R. Treatment of medication overuse headache guideline of the EFNS headache panel. Eur J Neurol. 2011;18:1115–21.CrossRefPubMed
16.
Zurück zum Zitat Tassorelli C, Diener HC, Dodick DW, Silberstein SD, Lipton RB, Ashina M, et al. International Headache Society Clinical Trials Standing Committee. Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia. 2018;38(5):815–32.CrossRefPubMed Tassorelli C, Diener HC, Dodick DW, Silberstein SD, Lipton RB, Ashina M, et al. International Headache Society Clinical Trials Standing Committee. Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia. 2018;38(5):815–32.CrossRefPubMed
17.
Zurück zum Zitat • Katsarava Z, Muessig M, Dzagnidze A, Fritsche G, Diener HC, Limmroth V. Medication overuse headache: rates and predictors for relapse in a 4-year prospective study. Cephalalgia. 2005;25:12–5. This is the first study addressing long-term relapse rate and providing data on the "protective" effect of triptans on relapse rate into MOH. CrossRefPubMed • Katsarava Z, Muessig M, Dzagnidze A, Fritsche G, Diener HC, Limmroth V. Medication overuse headache: rates and predictors for relapse in a 4-year prospective study. Cephalalgia. 2005;25:12–5. This is the first study addressing long-term relapse rate and providing data on the "protective" effect of triptans on relapse rate into MOH. CrossRefPubMed
18.
Zurück zum Zitat • Katsarava Z, Limmroth V, Finke M, Diener HC, Fritsche G. Rates and predictors for relapse in medication overuse headache: a 1-year prospective study. Neurology. 2003;60:1682–3. This is one of the the first study addressing medium-term relapse rate and providing data on the "protective" effect of triptans on relapse rate into MOH. CrossRefPubMed • Katsarava Z, Limmroth V, Finke M, Diener HC, Fritsche G. Rates and predictors for relapse in medication overuse headache: a 1-year prospective study. Neurology. 2003;60:1682–3. This is one of the the first study addressing medium-term relapse rate and providing data on the "protective" effect of triptans on relapse rate into MOH. CrossRefPubMed
19.
Zurück zum Zitat Rossi P, Faroni JV, Nappi G. Medication overuse headache: predictors and rates of relapse in migraine patients with low medical needs. A 1-year prospective study. Cephalalgia. 2008;28:1196–200.CrossRefPubMed Rossi P, Faroni JV, Nappi G. Medication overuse headache: predictors and rates of relapse in migraine patients with low medical needs. A 1-year prospective study. Cephalalgia. 2008;28:1196–200.CrossRefPubMed
20.
Zurück zum Zitat Biagianti B, Grazzi L, Usai S, Gambini O. Dependency-like behaviors and pain coping styles in subjects with chronic migraine and medication overuse: results from a 1-year follow-up study. BMC Neurol. 2014;14:181.CrossRefPubMedPubMedCentral Biagianti B, Grazzi L, Usai S, Gambini O. Dependency-like behaviors and pain coping styles in subjects with chronic migraine and medication overuse: results from a 1-year follow-up study. BMC Neurol. 2014;14:181.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Cargnin S, Viana M, Ghiotto N, Bianchi M, Sances G, Tassorelli C, et al. Functional polymorphisms in COMT and SLC6A4 genes influence the prognosis of patients with medication overuse headache after withdrawal therapy. Eur J Neurol. 2014;21:989–95.CrossRefPubMed Cargnin S, Viana M, Ghiotto N, Bianchi M, Sances G, Tassorelli C, et al. Functional polymorphisms in COMT and SLC6A4 genes influence the prognosis of patients with medication overuse headache after withdrawal therapy. Eur J Neurol. 2014;21:989–95.CrossRefPubMed
22.
Zurück zum Zitat Raggi A, Giovannetti AM, Leonardi M, Sansone E, Schiavolin S, Curone M, et al. Predictors of 12-months relapse after withdrawal treatment in hospitalized patients with chronic migraine associated with medication overuse: a longitudinal observational study. Headache. 2017;57:60–70.CrossRefPubMed Raggi A, Giovannetti AM, Leonardi M, Sansone E, Schiavolin S, Curone M, et al. Predictors of 12-months relapse after withdrawal treatment in hospitalized patients with chronic migraine associated with medication overuse: a longitudinal observational study. Headache. 2017;57:60–70.CrossRefPubMed
23.
Zurück zum Zitat Raggi A, Grazzi L, Ayadi R, Leonardi M, Proietti A, Schiavolin S, et al. Clinical and psychosocial features of frequent relapsers (FR) among patients with chronic migraine and medication overuse. Neurol Sci. 2017;38(Suppl 1):169–71.CrossRefPubMed Raggi A, Grazzi L, Ayadi R, Leonardi M, Proietti A, Schiavolin S, et al. Clinical and psychosocial features of frequent relapsers (FR) among patients with chronic migraine and medication overuse. Neurol Sci. 2017;38(Suppl 1):169–71.CrossRefPubMed
24.
Zurück zum Zitat Raggi A, Leonardi M, Scaratti C, Sansone E, Grazzi L, D’Amico D. Gender and education inequalities in the cost of medication-overuse headache. Neurol Sci. 2018;39(Suppl 1):117–9.CrossRefPubMed Raggi A, Leonardi M, Scaratti C, Sansone E, Grazzi L, D’Amico D. Gender and education inequalities in the cost of medication-overuse headache. Neurol Sci. 2018;39(Suppl 1):117–9.CrossRefPubMed
25.
Zurück zum Zitat D’Amico D, Grazzi L, Curone M, Leonardi M, Raggi A. Cost of medication overuse headache in Italian patients at the time-point of withdrawal: a retrospective study based on real data. Neurol Sci. 2017;38(Suppl 1):3–6.CrossRefPubMed D’Amico D, Grazzi L, Curone M, Leonardi M, Raggi A. Cost of medication overuse headache in Italian patients at the time-point of withdrawal: a retrospective study based on real data. Neurol Sci. 2017;38(Suppl 1):3–6.CrossRefPubMed
26.
Zurück zum Zitat D’Amico D, Mosconi P, Genco S, Usai S, Prudenzano AM, Grazzi L. Et al. The Migraine Disability Assessment (MIDAS) questionnaire: translation and reliability of the Italian version. Cephalalgia. 2001;21:947–52.CrossRefPubMed D’Amico D, Mosconi P, Genco S, Usai S, Prudenzano AM, Grazzi L. Et al. The Migraine Disability Assessment (MIDAS) questionnaire: translation and reliability of the Italian version. Cephalalgia. 2001;21:947–52.CrossRefPubMed
27.
Zurück zum Zitat Federici S, Bracalenti M, Meloni F, Luciano JV. World Health Organization disability assessment schedule 2.0: an international systematic review. Disabil Rehabil. 2017;39:2347–80.CrossRefPubMed Federici S, Bracalenti M, Meloni F, Luciano JV. World Health Organization disability assessment schedule 2.0: an international systematic review. Disabil Rehabil. 2017;39:2347–80.CrossRefPubMed
28.
Zurück zum Zitat Scaratti C, Covelli V, Guastafierro E, Leonardi M, Grazzi L, Rizzoli PB, et al. A qualitative study on patients with chronic migraine with medication overuse headache: comparing frequent and non-frequent relapsers. Headache. 2018 ( E-Pub ahead of print. https://doi.org/10.1111/head.13385). Scaratti C, Covelli V, Guastafierro E, Leonardi M, Grazzi L, Rizzoli PB, et al. A qualitative study on patients with chronic migraine with medication overuse headache: comparing frequent and non-frequent relapsers. Headache. 2018 ( E-Pub ahead of print. https://​doi.​org/​10.​1111/​head.​13385).
29.
Zurück zum Zitat •• Bigal ME, Lipton RB. Overuse of acute migraine medications and migraine chronification. Curr pain headache rep. 2009;13(4):301–7. This is one of the first and most important studies addressing the risk of chronification connected to the use of acute medications. CrossRefPubMed •• Bigal ME, Lipton RB. Overuse of acute migraine medications and migraine chronification. Curr pain headache rep. 2009;13(4):301–7. This is one of the first and most important studies addressing the risk of chronification connected to the use of acute medications. CrossRefPubMed
30.
Zurück zum Zitat •• Lipton RB, Serrano D, Nicholson RA, Buse DC, Runken MC, Reed ML. Impact of NSAID and Triptan use on developing chronic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2013;53(10):1548–63. This is a population study that addressed the risk of chronification connected to the use of triptans. CrossRefPubMed •• Lipton RB, Serrano D, Nicholson RA, Buse DC, Runken MC, Reed ML. Impact of NSAID and Triptan use on developing chronic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2013;53(10):1548–63. This is a population study that addressed the risk of chronification connected to the use of triptans. CrossRefPubMed
31.
Zurück zum Zitat Bigal ME, Lipton RB. Excessive opioid use and the development of chronic migraine. Pain. 2009;142(3):179–82.CrossRefPubMed Bigal ME, Lipton RB. Excessive opioid use and the development of chronic migraine. Pain. 2009;142(3):179–82.CrossRefPubMed
32.
Zurück zum Zitat Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. AMPP advisory group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343–9.CrossRefPubMed Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. AMPP advisory group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343–9.CrossRefPubMed
33.
Zurück zum Zitat Biondi DM. Opioid resistance in chronic daily headache: a synthesis of ideas from the bench and bedside. Curr Pain Headache Rep. 2003;7(1):67–75.CrossRefPubMed Biondi DM. Opioid resistance in chronic daily headache: a synthesis of ideas from the bench and bedside. Curr Pain Headache Rep. 2003;7(1):67–75.CrossRefPubMed
34.
Zurück zum Zitat Wilkinson SM, Becker WJ, Heine JA. Opiate use to control bowel motility may induce chronic daily headache in patients with migraine. Headache. 2001;41(3):303–9.CrossRefPubMed Wilkinson SM, Becker WJ, Heine JA. Opiate use to control bowel motility may induce chronic daily headache in patients with migraine. Headache. 2001;41(3):303–9.CrossRefPubMed
35.
Zurück zum Zitat Rothrock JF. The case for opiate/opioid therapy in the management of headache. Headache. 2012;52(Suppl 1):35–7.CrossRefPubMed Rothrock JF. The case for opiate/opioid therapy in the management of headache. Headache. 2012;52(Suppl 1):35–7.CrossRefPubMed
36.
Zurück zum Zitat Sarchielli P, Granella F, Prudenzano MP, Pini LA, Guidetti V, Bono G, et al. Italian guidelines for primary headaches: 2012 revised version. J Headache Pain. 2012;13(Suppl 2):31–70.CrossRefPubMedCentral Sarchielli P, Granella F, Prudenzano MP, Pini LA, Guidetti V, Bono G, et al. Italian guidelines for primary headaches: 2012 revised version. J Headache Pain. 2012;13(Suppl 2):31–70.CrossRefPubMedCentral
37.
Zurück zum Zitat Dodick DW. Review of comorbidities and risk factors for the development of migraine complications (infarct and chronic migraine). Cephalalgia. 2009;29(Suppl 3):7–14.PubMed Dodick DW. Review of comorbidities and risk factors for the development of migraine complications (infarct and chronic migraine). Cephalalgia. 2009;29(Suppl 3):7–14.PubMed
38.
Zurück zum Zitat Sandrini G, Cerbo R, Del Bene E, Ferrari A, Genco S, Grazioli I, et al. Efficacy of dosing and re-dosing of two oral fixed combinations of indomethacin, prochlorperazine and caffeine compared with oral sumatriptan in the acute treatment of multiple migraine attacks: a double-blind, double-dummy, randomized, parallel group, multicentre study. Int J Clin Pract. 2007;61(8):1256–69.CrossRefPubMedPubMedCentral Sandrini G, Cerbo R, Del Bene E, Ferrari A, Genco S, Grazioli I, et al. Efficacy of dosing and re-dosing of two oral fixed combinations of indomethacin, prochlorperazine and caffeine compared with oral sumatriptan in the acute treatment of multiple migraine attacks: a double-blind, double-dummy, randomized, parallel group, multicentre study. Int J Clin Pract. 2007;61(8):1256–69.CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat • Scher AI1, Lipton RB, Stewart WF, Bigal M. Patterns of medication use by chronic and episodic headache sufferers in the general population: results from the frequent headache epidemiology study. Cephalalgia. 2010;30(3):321–8. This is one of the most important population studies investigating the pattern of consumption of acute medications among CDH sufferers. CrossRefPubMed • Scher AI1, Lipton RB, Stewart WF, Bigal M. Patterns of medication use by chronic and episodic headache sufferers in the general population: results from the frequent headache epidemiology study. Cephalalgia. 2010;30(3):321–8. This is one of the most important population studies investigating the pattern of consumption of acute medications among CDH sufferers. CrossRefPubMed
40.
Zurück zum Zitat Ferrari A, Savino G, Gallesi D, Pinetti D, Bertolini A, Sances G, et al. Effect of overuse of the antimigraine combination of indomethacin, prochlorperazine and caffeine (IPC) on the disposition of its components in chronic headache patients. Pharmacol Res. 2006;54(2):142–9.CrossRefPubMed Ferrari A, Savino G, Gallesi D, Pinetti D, Bertolini A, Sances G, et al. Effect of overuse of the antimigraine combination of indomethacin, prochlorperazine and caffeine (IPC) on the disposition of its components in chronic headache patients. Pharmacol Res. 2006;54(2):142–9.CrossRefPubMed
41.
Zurück zum Zitat Jonsson P, Jakobsson A, Hensing G, Linde M, Moore CD, Hedenrud T. Holding on to the indispensable medication--a grounded theory on medication use from the perspective of persons with medication overuse headache. J Headache Pain. 2013;14:43.CrossRefPubMedPubMedCentral Jonsson P, Jakobsson A, Hensing G, Linde M, Moore CD, Hedenrud T. Holding on to the indispensable medication--a grounded theory on medication use from the perspective of persons with medication overuse headache. J Headache Pain. 2013;14:43.CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat Nichols VP, Ellard DR, Griffiths FE, Kamal A, Underwood M, SJC T. CHESS team. The lived experience of chronic headache: a systematic review and synthesis of the qualitative literature. BMJ Open. 2017;7(12):e019929.CrossRefPubMedPubMedCentral Nichols VP, Ellard DR, Griffiths FE, Kamal A, Underwood M, SJC T. CHESS team. The lived experience of chronic headache: a systematic review and synthesis of the qualitative literature. BMJ Open. 2017;7(12):e019929.CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Engstrom M, Hagen K, Bjork MH, Stovner LJ, Gravdahl GB, Stjern M, et al. Sleep quality, arousal and pain thresholds in migraineurs: a blinded controlled polysomnographic study. J Headache Pain. 2013;14:1–12.CrossRef Engstrom M, Hagen K, Bjork MH, Stovner LJ, Gravdahl GB, Stjern M, et al. Sleep quality, arousal and pain thresholds in migraineurs: a blinded controlled polysomnographic study. J Headache Pain. 2013;14:1–12.CrossRef
44.
Zurück zum Zitat Florencio LL, Giantomassi MC, Carvalho GF, Gonçalves MC, Dach F, Fernández-de-Las-Peñas C, et al. Generalized pressure pain hypersensitivity in the cervical muscles in women with migraine. Pain Med. 2015;16:1629–34.CrossRefPubMed Florencio LL, Giantomassi MC, Carvalho GF, Gonçalves MC, Dach F, Fernández-de-Las-Peñas C, et al. Generalized pressure pain hypersensitivity in the cervical muscles in women with migraine. Pain Med. 2015;16:1629–34.CrossRefPubMed
45.
Zurück zum Zitat Weissman-Fogel I, Sprecher E, Granovsky Y, Yarnitsky M. Repeated noxious stimulation of the skin enhances cutaneous pain perception of migraine patients in-between attacks: clinical evidence for continuous sub-threshold increase in membrane excitability of central trigeminovascular neurons. Pain. 2003;104:693–700.CrossRefPubMed Weissman-Fogel I, Sprecher E, Granovsky Y, Yarnitsky M. Repeated noxious stimulation of the skin enhances cutaneous pain perception of migraine patients in-between attacks: clinical evidence for continuous sub-threshold increase in membrane excitability of central trigeminovascular neurons. Pain. 2003;104:693–700.CrossRefPubMed
46.
Zurück zum Zitat Lipton RB, Bigal ME, Ashina S, Burstein R, Silberstein S, Reed ML, et al. Cutaneous allodynia in the migraine population. Ann Neurol. 2008;63:148–58.CrossRefPubMedPubMedCentral Lipton RB, Bigal ME, Ashina S, Burstein R, Silberstein S, Reed ML, et al. Cutaneous allodynia in the migraine population. Ann Neurol. 2008;63:148–58.CrossRefPubMedPubMedCentral
47.
Zurück zum Zitat Baykan B, Ekizoglu E, Karli N, Kocasoy-Orhan E, Zarifoglu M, Saip S, et al. Characterization of migraineurs having allodynia: results of a large population-based study. Clin J Pain. 2016;32:631–5.CrossRefPubMed Baykan B, Ekizoglu E, Karli N, Kocasoy-Orhan E, Zarifoglu M, Saip S, et al. Characterization of migraineurs having allodynia: results of a large population-based study. Clin J Pain. 2016;32:631–5.CrossRefPubMed
48.
Zurück zum Zitat Mathur VA, Moayedi M, Keaser ML, Khan SA, Hubbard CS, Goyal M, et al. High frequency migraine is associated with lower acute pain sensitivity and abnormal insula activity related to migraine pain intensity, attack frequency, and pain catastrophizing. Front Hum Neurosci. 2016;10:489.CrossRefPubMedPubMedCentral Mathur VA, Moayedi M, Keaser ML, Khan SA, Hubbard CS, Goyal M, et al. High frequency migraine is associated with lower acute pain sensitivity and abnormal insula activity related to migraine pain intensity, attack frequency, and pain catastrophizing. Front Hum Neurosci. 2016;10:489.CrossRefPubMedPubMedCentral
49.
Zurück zum Zitat Hubbard CS, Khan SA, Keaser ML, Mathur VA, Goyal M, Seminowicz DA. Altered brain structure and function correlate with disease severity and pain catastrophizing in migraine patients. eNeuro. 2014;1(1):e20.14.CrossRefPubMed Hubbard CS, Khan SA, Keaser ML, Mathur VA, Goyal M, Seminowicz DA. Altered brain structure and function correlate with disease severity and pain catastrophizing in migraine patients. eNeuro. 2014;1(1):e20.14.CrossRefPubMed
50.
Zurück zum Zitat Schwedt TJ, Alam A, Reed ML, Fanning KM, Munjal S, Buse DC, et al. Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study. J Headache Pain. 2018;19(1):38.CrossRefPubMedPubMedCentral Schwedt TJ, Alam A, Reed ML, Fanning KM, Munjal S, Buse DC, et al. Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study. J Headache Pain. 2018;19(1):38.CrossRefPubMedPubMedCentral
51.
Zurück zum Zitat Louter MA, Bosker JE, van Oosterhout WP, van Zwet EW, Zitman FG, Ferrari MD, et al. Cutaneous allodynia as a predictor of migraine chronification. Brain. 2013;136(Pt 11):3489–96.CrossRefPubMed Louter MA, Bosker JE, van Oosterhout WP, van Zwet EW, Zitman FG, Ferrari MD, et al. Cutaneous allodynia as a predictor of migraine chronification. Brain. 2013;136(Pt 11):3489–96.CrossRefPubMed
52.
Zurück zum Zitat Bigal ME, Lipton RB. What predicts the change from episodic to chronic migraine? Curr Opin Neurol. 2009;22(3):269–76.CrossRefPubMed Bigal ME, Lipton RB. What predicts the change from episodic to chronic migraine? Curr Opin Neurol. 2009;22(3):269–76.CrossRefPubMed
53.
Zurück zum Zitat Leonardi M, Raggi A, Bussone G, D’Amico D. Health-related quality of life, disability and severity of disease in patients with migraine attending to a specialty headache center. Headache. 2010;50:1576–86.CrossRefPubMed Leonardi M, Raggi A, Bussone G, D’Amico D. Health-related quality of life, disability and severity of disease in patients with migraine attending to a specialty headache center. Headache. 2010;50:1576–86.CrossRefPubMed
54.
Zurück zum Zitat Raggi A, Grazzi L, Grignani E, Leonardi M, Sansone E, Scaratti C, et al. The use of MIDAS in patients with chronic migraine and medication-overuse headache: should we trust it? Neurol Sci. 2018;39(Suppl 1):125–7.CrossRefPubMed Raggi A, Grazzi L, Grignani E, Leonardi M, Sansone E, Scaratti C, et al. The use of MIDAS in patients with chronic migraine and medication-overuse headache: should we trust it? Neurol Sci. 2018;39(Suppl 1):125–7.CrossRefPubMed
55.
Zurück zum Zitat Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001;358(9294):1668–75.CrossRefPubMed Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001;358(9294):1668–75.CrossRefPubMed
56.
Zurück zum Zitat Cameron C, Kelly S, Hsieh SC, Murphy M, Chen L, Kotb A, et al. Triptans in the acute treatment of migraine: a systematic review and network meta-analysis. Headache. 2015;55(Suppl 4):221–35.CrossRefPubMed Cameron C, Kelly S, Hsieh SC, Murphy M, Chen L, Kotb A, et al. Triptans in the acute treatment of migraine: a systematic review and network meta-analysis. Headache. 2015;55(Suppl 4):221–35.CrossRefPubMed
57.
Zurück zum Zitat Thorlund K, Mills EJ, Wu P, Ramos E, Chatterjee A, Druyts E, et al. Comparative efficacy of triptans for the abortive treatment of migraine: a multiple treatment comparison meta-analysis. Cephalalgia. 2014;34(4):258–67.CrossRefPubMed Thorlund K, Mills EJ, Wu P, Ramos E, Chatterjee A, Druyts E, et al. Comparative efficacy of triptans for the abortive treatment of migraine: a multiple treatment comparison meta-analysis. Cephalalgia. 2014;34(4):258–67.CrossRefPubMed
58.
Zurück zum Zitat Ashaye T, Hounsome N, Carnes D, Taylor SJC, Homer K, Eldridge S, et al. COPERS Study Team (ISRCTN 24426731). Opioid prescribing for chronic musculoskeletal pain in UK primary care: results from a cohort analysis of the COPERS trial. BMJ Open. 2018;8(6):e019491.PubMedPubMedCentral Ashaye T, Hounsome N, Carnes D, Taylor SJC, Homer K, Eldridge S, et al. COPERS Study Team (ISRCTN 24426731). Opioid prescribing for chronic musculoskeletal pain in UK primary care: results from a cohort analysis of the COPERS trial. BMJ Open. 2018;8(6):e019491.PubMedPubMedCentral
59.
Zurück zum Zitat Hakkarainen H, Gustafsson B, Stockman O. A comparative trail of ergotamine tartrate, acetyl salicylic acid and a dextropropoxyphene compound in acute migraine attacks. Headache. 1978;18(1):35–9.CrossRefPubMed Hakkarainen H, Gustafsson B, Stockman O. A comparative trail of ergotamine tartrate, acetyl salicylic acid and a dextropropoxyphene compound in acute migraine attacks. Headache. 1978;18(1):35–9.CrossRefPubMed
60.
Zurück zum Zitat Anneken K, Evers S, Husstedt IW. Efficacy of fixed combinations of acetylsalicyclic acid, acetaminophen and caffeine in the treatment of idiopathic headache: a review. Eur J Neurol. 2010;17(4):534–e25.CrossRefPubMed Anneken K, Evers S, Husstedt IW. Efficacy of fixed combinations of acetylsalicyclic acid, acetaminophen and caffeine in the treatment of idiopathic headache: a review. Eur J Neurol. 2010;17(4):534–e25.CrossRefPubMed
61.
Zurück zum Zitat Bigal ME, Lipton RB. Excessive acute migraine medication use and migraine progression. Neurology. 2008;71(22):1821–8.CrossRefPubMed Bigal ME, Lipton RB. Excessive acute migraine medication use and migraine progression. Neurology. 2008;71(22):1821–8.CrossRefPubMed
62.
Zurück zum Zitat Lipton RB. Ergotamine tartrate and dihydroergotamine mesylate: safety profiles. Headache. 1997;37(Suppl 1):33–41. Lipton RB. Ergotamine tartrate and dihydroergotamine mesylate: safety profiles. Headache. 1997;37(Suppl 1):33–41.
63.
Zurück zum Zitat Raggi A, Grignani E, Leonardi M, Andrasik F, Sansone E, Grazzi L, et al. Behavioral approaches for primary headaches: recent advances. Headache. 2018;58(6):913–25.CrossRefPubMed Raggi A, Grignani E, Leonardi M, Andrasik F, Sansone E, Grazzi L, et al. Behavioral approaches for primary headaches: recent advances. Headache. 2018;58(6):913–25.CrossRefPubMed
64.
Zurück zum Zitat Andrasik F, Grazzi L, D’Amico D, Sansone E, Leonardi M, Raggi A, et al. Mindfulness and headache: a "new" old treatment, with new findings. Cephalalgia. 2016;36(12):1192–205.CrossRefPubMed Andrasik F, Grazzi L, D’Amico D, Sansone E, Leonardi M, Raggi A, et al. Mindfulness and headache: a "new" old treatment, with new findings. Cephalalgia. 2016;36(12):1192–205.CrossRefPubMed
Metadaten
Titel
Is Medication Overuse Drug Specific or Not? Data from a Review of Published Literature and from an Original Study on Italian MOH Patients
verfasst von
Licia Grazzi
Eleonora Grignani
Domenico D’Amico
Emanuela Sansone
Alberto Raggi
Publikationsdatum
01.11.2018
Verlag
Springer US
Erschienen in
Current Pain and Headache Reports / Ausgabe 11/2018
Print ISSN: 1531-3433
Elektronische ISSN: 1534-3081
DOI
https://doi.org/10.1007/s11916-018-0729-x

Weitere Artikel der Ausgabe 11/2018

Current Pain and Headache Reports 11/2018 Zur Ausgabe

Uncommon and/or Unusual Headaches and Syndromes (J Ailani, Section Editor)

Current Aura Without Headache

Other Pain (A Kaye and N Vadivelu, Section Editors)

The Evolution of Surgical Enhanced Recovery Pathways: a Review

Hot Topics in Pain and Headache (N Rosen, Section Editor)

Naloxone Academic Detailing: Role of Community Outreach Teaching

Hot Topics in Pain and Headache (N Rosen, Section Editor)

The Evolving Landscape of Acute Pain Management in the Era of the Opioid Crisis

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.